GlassScriptPhysician profile
Dawn Newman
NPI 1881233930
$3,791.10
in general payments reported to CMS, 2019-2025
25 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $804 · 2023: $1,004 · 2024: $1,413 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Education: $40.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.11 |
| Education | $40.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.07 | 2021-2025 | |
| Novo Nordisk INC | $729.61 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $402.63 | 2023-2025 | Airsupra, Breztri |
| Pfizer INC. | $361.64 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $245.38 | 2022 | |
| Tolmar, INC. | $158.72 | 2023-2025 | Jatenzo |
| Axsome Therapeutics, INC. | $116.62 | 2024-2025 | Auvelity |
| Cumberland Pharmaceuticals, INC. | $115.46 | 2021-2024 | Kristalose |
| Corium, LLC | $113.19 | 2022-2024 | Azstarys, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $94.73 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $89.41 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $81.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cranial Technologies, INC | $55.55 | 2021-2024 | Doc Band |
| Cognoa, INC. | $54.81 | 2021-2022 | |
| Alk-Abello, INC | $54.65 | 2023-2025 | Neffy, Odactra, Ragwitek |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $52.53 | 2021 | |
| Lundbeck LLC | $43.36 | 2023-2024 | Rexulti |
| Impel Pharmaceuticals INC. | $18.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.59 | 2024 | |
| Janssen Biotech, INC. | $15.14 | 2022 | |
| Tris Pharma INC | $14.61 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.54 | 2024 | Caplyta |
| Ani Pharmaceuticals, INC. | $13.30 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $12.64 | 2021 | |
| Merck Sharp & Dohme LLC | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.